This study examined the use of SV40 vectors carrying siRNA in patients diagnosed with chronic myeloid leukaemia (CML). The approach uses a viral vector to deliver small interfering RNA in order to silence the disease-driving gene product. Adults aged 18 and over with CML took part, and the study has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Diagnosis of CML Exclusion Criteria: * Under 18 years old * Pregnant